Aviceda is a Cambridge, MA‑based, clinical‑stage biotech focused on ophthalmic and broader immunomodulatory therapeutics built on its High Affinity Ligands of Siglecs (HALOS™) nanotechnology platform. Its lead asset, AVD‑104, is an intravitreal glycan‑coated nanoparticle with a dual mechanism that repolarizes inflammatory microglia/macrophages and inhibits complement cascade amplification. AVD‑104 showed proof‑of‑concept efficacy in a Phase 2a trial completed in early 2024 and is being evaluated in a fully enrolled Phase 2b/3 trial with 12‑month data expected in the second half of 2025. The company intends to use recent financing proceeds to complete the ongoing Phase 2b/3 and to support a planned pivotal Phase 3 program, and to expand into other ophthalmic indications. Aviceda also reports a broader pipeline across ophthalmology and other therapeutic areas including immunology, fibrosis, oncology, and neurology. Board and governance changes accompanying recent financing are intended to support late‑stage development and commercialization planning.

Total raised

$208M

Funding rounds

1

Latest round

Series C

Latest activity

Jan 2025